Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

“In fact, we think VGX-3100 (HPV program) and INO-5401 (GBM program) will be the main value drivers for Inovio moving forward, and while we don’t expect any catalysts for these programs in 1H22, we expect readouts for INO-4500 in Lassa fever and INO-3107 in RRP in 1H22 to further de-risk the platform and add momentum to the story,” he added.

1/21/22 BofA analyst Geoff Meacham upgraded Inovio to Neutral from Underperform with a price target of $10, up from $8. The analyst cites the stock's recent weakness and contends that the majority of remaining COVID-19 value has been removed from valuation following the recent 18% year-to-date pullback. Meacham adds that Inovio's commercial outlook for its COVID-19 vaccine has not changed, and the data generated from the program has demonstrated a favorable safety-profile and robust efficacy.

https://markets.businessinsider.com/news/stocks/why-this-analyst-has-increased-confidence-in-inovio-pharmaceuticals-1031119562
https://thefly.com/news.php?symbol=INO